These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
336 related articles for article (PubMed ID: 30792455)
1. Impact of sarcopenia in patients with advanced non-small cell lung cancer treated with PD-1 inhibitors: A preliminary retrospective study. Shiroyama T; Nagatomo I; Koyama S; Hirata H; Nishida S; Miyake K; Fukushima K; Shirai Y; Mitsui Y; Takata S; Masuhiro K; Yaga M; Iwahori K; Takeda Y; Kida H; Kumanogoh A Sci Rep; 2019 Feb; 9(1):2447. PubMed ID: 30792455 [TBL] [Abstract][Full Text] [Related]
2. Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer. Toi Y; Sugawara S; Sugisaka J; Ono H; Kawashima Y; Aiba T; Kawana S; Saito R; Aso M; Tsurumi K; Suzuki K; Shimizu H; Domeki Y; Terayama K; Nakamura A; Yamanda S; Kimura Y; Honda Y JAMA Oncol; 2019 Mar; 5(3):376-383. PubMed ID: 30589930 [TBL] [Abstract][Full Text] [Related]
3. Clinical impact of skeletal muscle area in patients with non-small cell lung cancer treated with anti-PD-1 inhibitors. Takada K; Yoneshima Y; Tanaka K; Okamoto I; Shimokawa M; Wakasu S; Takamori S; Toyokawa G; Oba T; Osoegawa A; Tagawa T; Oda Y; Nakanishi Y; Mori M J Cancer Res Clin Oncol; 2020 May; 146(5):1217-1225. PubMed ID: 32025867 [TBL] [Abstract][Full Text] [Related]
4. Skeletal muscle mass predicts the outcome of nivolumab treatment for non-small cell lung cancer. Tsukagoshi M; Yokobori T; Yajima T; Maeno T; Shimizu K; Mogi A; Araki K; Harimoto N; Shirabe K; Kaira K Medicine (Baltimore); 2020 Feb; 99(7):e19059. PubMed ID: 32049805 [TBL] [Abstract][Full Text] [Related]
5. Prognostic Impact and Risk Factors of Immune-Related Pneumonitis in Patients With Non-Small-Cell Lung Cancer Who Received Programmed Death 1 Inhibitors. Fukihara J; Sakamoto K; Koyama J; Ito T; Iwano S; Morise M; Ogawa M; Kondoh Y; Kimura T; Hashimoto N; Hasegawa Y Clin Lung Cancer; 2019 Nov; 20(6):442-450.e4. PubMed ID: 31446020 [TBL] [Abstract][Full Text] [Related]
6. Predictive value of oncogenic driver subtype, programmed death-1 ligand (PD-L1) score, and smoking status on the efficacy of PD-1/PD-L1 inhibitors in patients with oncogene-driven non-small cell lung cancer. Ng TL; Liu Y; Dimou A; Patil T; Aisner DL; Dong Z; Jiang T; Su C; Wu C; Ren S; Zhou C; Camidge DR Cancer; 2019 Apr; 125(7):1038-1049. PubMed ID: 30548240 [TBL] [Abstract][Full Text] [Related]
7. Retreatment with pembrolizumab in advanced non-small cell lung cancer patients previously treated with nivolumab: emerging reports of 12 cases. Fujita K; Uchida N; Kanai O; Okamura M; Nakatani K; Mio T Cancer Chemother Pharmacol; 2018 Jun; 81(6):1105-1109. PubMed ID: 29675747 [TBL] [Abstract][Full Text] [Related]
8. Pretreatment advanced lung cancer inflammation index (ALI) for predicting early progression in nivolumab-treated patients with advanced non-small cell lung cancer. Shiroyama T; Suzuki H; Tamiya M; Tamiya A; Tanaka A; Okamoto N; Nakahama K; Taniguchi Y; Isa SI; Inoue T; Imamura F; Atagi S; Hirashima T Cancer Med; 2018 Jan; 7(1):13-20. PubMed ID: 29150906 [TBL] [Abstract][Full Text] [Related]
9. Comparative effectiveness of pembrolizumab vs. nivolumab in patients with recurrent or advanced NSCLC. Cui P; Li R; Huang Z; Wu Z; Tao H; Zhang S; Hu Y Sci Rep; 2020 Aug; 10(1):13160. PubMed ID: 32753702 [TBL] [Abstract][Full Text] [Related]
10. Characteristics of Real-World Metastatic Non-Small Cell Lung Cancer Patients Treated with Nivolumab and Pembrolizumab During the Year Following Approval. Khozin S; Abernethy AP; Nussbaum NC; Zhi J; Curtis MD; Tucker M; Lee SE; Light DE; Gossai A; Sorg RA; Torres AZ; Patel P; Blumenthal GM; Pazdur R Oncologist; 2018 Mar; 23(3):328-336. PubMed ID: 29317551 [TBL] [Abstract][Full Text] [Related]
11. Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients. Cortellini A; Chiari R; Ricciuti B; Metro G; Perrone F; Tiseo M; Bersanelli M; Bordi P; Santini D; Giusti R; Grassadonia A; Di Marino P; Tinari N; De Tursi M; Zoratto F; Veltri E; Malorgio F; Garufi C; Russano M; Anesi C; Zeppola T; Filetti M; Marchetti P; Berardi R; Rinaldi S; Tudini M; Silva RR; Pireddu A; Atzori F; Iacono D; Migliorino MR; Porzio G; Cannita K; Ficorella C; Buti S Clin Lung Cancer; 2019 Jul; 20(4):237-247.e1. PubMed ID: 30885550 [TBL] [Abstract][Full Text] [Related]
12. Comprehensive analysis of the characteristics and treatment outcomes of patients with non-small cell lung cancer treated with anti-PD-1 therapy in real-world practice. Ahn BC; Pyo KH; Xin CF; Jung D; Shim HS; Lee CY; Park SY; Yoon HI; Hong MH; Cho BC; Kim HR J Cancer Res Clin Oncol; 2019 Jun; 145(6):1613-1623. PubMed ID: 30911841 [TBL] [Abstract][Full Text] [Related]
13. Retreatment With Anti-PD-L1 Antibody in Advanced Non-small Cell Lung Cancer Previously Treated With Anti-PD-1 Antibodies. Fujita K; Uchida N; Yamamoto Y; Kanai O; Okamura M; Nakatani K; Sawai S; Mio T Anticancer Res; 2019 Jul; 39(7):3917-3921. PubMed ID: 31262921 [TBL] [Abstract][Full Text] [Related]
14. The efficacy and safety of nivolumab, pembrolizumab, and atezolizumab in treatment of advanced non-small cell lung cancer. Chen R; Tao Y; Xu X; Shan L; Jiang H; Yin Q; Pei L; Cai F; Ma L; Yu Y Discov Med; 2018 Oct; 26(143):155-166. PubMed ID: 30586539 [TBL] [Abstract][Full Text] [Related]
15. Predictive value of serum protein levels in patients with advanced non-small cell lung cancer treated with nivolumab. Oyanagi J; Koh Y; Sato K; Mori K; Teraoka S; Akamatsu H; Kanai K; Hayata A; Tokudome N; Akamatsu K; Nakanishi M; Ueda H; Yamamoto N Lung Cancer; 2019 Jun; 132():107-113. PubMed ID: 31097082 [TBL] [Abstract][Full Text] [Related]
16. Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer. Bagley SJ; Kothari S; Aggarwal C; Bauml JM; Alley EW; Evans TL; Kosteva JA; Ciunci CA; Gabriel PE; Thompson JC; Stonehouse-Lee S; Sherry VE; Gilbert E; Eaby-Sandy B; Mutale F; DiLullo G; Cohen RB; Vachani A; Langer CJ Lung Cancer; 2017 Apr; 106():1-7. PubMed ID: 28285682 [TBL] [Abstract][Full Text] [Related]
17. Speed of Adoption of Immune Checkpoint Inhibitors of Programmed Cell Death 1 Protein and Comparison of Patient Ages in Clinical Practice vs Pivotal Clinical Trials. O'Connor JM; Fessele KL; Steiner J; Seidl-Rathkopf K; Carson KR; Nussbaum NC; Yin ES; Adelson KB; Presley CJ; Chiang AC; Ross JS; Abernethy AP; Gross CP JAMA Oncol; 2018 Aug; 4(8):e180798. PubMed ID: 29800974 [TBL] [Abstract][Full Text] [Related]
18. Efficacy of Nivolumab and Pembrolizumab in Patients With Advanced Non-Small-Cell Lung Cancer Needing Treatment Interruption Because of Adverse Events: A Retrospective Multicenter Analysis. Ksienski D; Wai ES; Croteau N; Fiorino L; Brooks E; Poonja Z; Fenton D; Geller G; Glick D; Lesperance M Clin Lung Cancer; 2019 Jan; 20(1):e97-e106. PubMed ID: 30337270 [TBL] [Abstract][Full Text] [Related]
19. Toxicity management with combination chemotherapy and programmed death 1/programmed death ligand 1 inhibitor therapy in advanced lung cancer. Hoffner B; Leighl NB; Davies M Cancer Treat Rev; 2020 Apr; 85():101979. PubMed ID: 32078962 [TBL] [Abstract][Full Text] [Related]
20. Efficacy of local therapy for oligoprogressive disease after programmed cell death 1 blockade in advanced non-small cell lung cancer. Kagawa Y; Furuta H; Uemura T; Watanabe N; Shimizu J; Horio Y; Kuroda H; Inaba Y; Kodaira T; Masago K; Fujita S; Niimi A; Hida T Cancer Sci; 2020 Dec; 111(12):4442-4452. PubMed ID: 32770608 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]